# Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

> **NCT05079152** · PHASE4 · UNKNOWN · sponsor: **China National Biotec Group Company Limited** · enrollment: 1404 (actual)

## Conditions studied

- Influenza, Human
- Pneumonia, Pneumococcal
- COVID-19 Pneumonia

## Interventions

- **BIOLOGICAL:** COVAX+PPV23;COVAX+IIV4
- **BIOLOGICAL:** COVAX only (1st and 2nd dose)
- **BIOLOGICAL:** PPV23 for the 1st dose and IIV4 for the 2nd dose

## Key facts

- **NCT ID:** NCT05079152
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-06
- **Primary completion:** 2021-05-29
- **Final completion:** 2021-12
- **Target enrollment:** 1404 (ACTUAL)
- **Last updated:** 2021-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05079152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05079152, "Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05079152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*